LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Kodu・Aktsiate loetelu・Champions Oncology Inc

C
Champions Oncology Inc

Suletud

SektorTervishoid

5.83 -4.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.76

Max

6.43

Põhinäitajad
By Trading Economics
Sissetulek	702K 236K
Müük	1M 15M
P/E Sektori keskmine	38.529 121.746
Kasumimarginaal	1.57
Töötajad	213
EBITDA	1.1M 612K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+83.21% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-17M 91M
Eelmine avamishind	9.94
Eelmine sulgemishind	5.83

Uudiste sentiment

By Acuity

50%

149 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

5.77 / 7.61 Toetus ja vastupanu

Champions Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. veebr 2026, 23:47 UTC

Kuumad aktsiad

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11. veebr 2026, 22:59 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Grab Holdings to Buy U.S.-Based Stash Financial

11. veebr 2026, 23:54 UTC

Tulu

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11. veebr 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11. veebr 2026, 23:49 UTC

Tulu

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11. veebr 2026, 23:45 UTC

Tulu

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11. veebr 2026, 23:42 UTC

Tulu

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11. veebr 2026, 23:41 UTC

Tulu

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11. veebr 2026, 23:40 UTC

Tulu

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11. veebr 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11. veebr 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11. veebr 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11. veebr 2026, 22:58 UTC

Tulu

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11. veebr 2026, 22:57 UTC

Tulu

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11. veebr 2026, 22:54 UTC

Tulu

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11. veebr 2026, 22:53 UTC

Tulu

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:23 UTC

Tulu

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11. veebr 2026, 22:19 UTC

Tulu

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11. veebr 2026, 22:16 UTC

Tulu

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Võrdlus sarnastega

Hinnamuutus

Champions Oncology Inc Prognoos

Hinnasiht

By TipRanks

83.21% tõus

12 kuu keskmine prognoos

Keskmine 12 USD 83.21%

Kõrge 12 USD

Madal 12 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Champions Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Champions Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.77 / 7.61Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

149 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.